“…Known centrally acting morpholine-containing compounds include stimulants/anorectics (phenmetrazine and analogues); dissociative anesthetics (phencyclidine analogues); anticonvulsants (imepitoin); antiemetics (azasetron, aprepitant, and analogues); antidepressants (reboxetine, moclobemide, and viloxazine); tranquilizers (trimetozine); antipsychotics (molindone); central analgesics (pravadoline and analogues); opioids (dextromoramide, morpheridine, phenadoxone, and pholcodine); non-opioid central antitussives (morclofone and pentethylcyclanone); and antiparkinsonian (foliglurax and tozadenant), neuroprotective (WIN 55,212-2 and PRE-084), and nootropic (CX717 and A-349,821) agents [ 5 ]. Potential indications for morpholine-based drugs may, in turn, include Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, multiple sclerosis, lateral amyotrophic sclerosis, traumatic brain injury, and ischemic stroke [ 12 ].…”